Chicago Partners Investment Group 13F: Adds $8.6M to NVO Stake
Key Points
- Chicago Partners Investment Group increased its position in Novo Nordisk A by 219,067 shares, now holding 241,798 shares valued at approximately $9.44 million.
- The fund's total reported value in its 13F filing was about $1.51 billion, with Novo Nordisk making up 0.62% of its portfolio.
- Novo Nordisk shares recently traded around $38.67, which is about 1.2% below the closing price of $39.13 on October 26, 2026.
Get Novo Nordisk A text alerts
We text you when insiders, Congress, analysts or big funds move on $NVO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Novo Nordisk A alert may contain errors. Disclosures
On October 27, 2026, Chicago Partners Investment Group boosted its stake in Novo Nordisk A (NVO) by 219,067 shares, bringing its total to 241,798 shares. This increase is valued at approximately $9.44 million, according to the fund's latest Form 13F filing with the SEC.
NVO
Novo Nordisk A
Chicago Partners Investment Group vs. the S&P 500
Hypothetical returns from Chicago Partners Investment Group's disclosed trades, not real profit or advice. How we model this.
What Changed in Chicago Partners Investment Group's Novo Nordisk Position
The fund's stake in Novo Nordisk increased significantly, showing a 963.7% change in its holdings. The total reported value of Chicago Partners' investment in Novo Nordisk is about $9.44 million, which represents 0.62% of the fund's overall portfolio.
Where Novo Nordisk Fits in Chicago Partners Investment Group's Portfolio
Novo Nordisk ranks 27th among the 1,660 positions in Chicago Partners' portfolio. The recent boost adds a considerable number of shares to their existing position, reflecting a notable investment in the healthcare sector.
Other Institutional Activity in Novo Nordisk
Dodge & Cox Inc. holds 20,397,110 shares of Novo Nordisk, increasing its stake by 1,063,356 shares. LOOMIS SAYLES & CO L P also raised its position, adding 1,577,465 shares for a total of 18,594,352 shares. In contrast, Franklin Resources, Inc. reduced its stake by 3,043,140 shares, now holding 13,041,109 shares.
Novo Nordisk A Stock Down 1.0%
Novo Nordisk shares recently traded around $38.67, which is about 1.2% below the closing price of $39.13 on October 26, 2026. The stock is also trading significantly below its 52-week high of $64.16, and about 39.7% lower than that peak.
Recent Earnings
Novo Nordisk reported trailing twelve-month revenue of approximately $329.43 billion, with a net margin of 35.3% and an EPS of $4.13. The next earnings report is scheduled for November 4, 2026.
Dividend
Novo Nordisk pays an annual dividend of $1.80 per share, which gives it a dividend yield of 4.59%.
Insider Buying and Selling at Novo Nordisk A
There are currently no reported insider trades at Novo Nordisk A.
Analysts Set New Price Targets
On September 11, 2026, Morgan Stanley downgraded Novo Nordisk to an Underweight rating with a price target of $40.00. BMO Capital maintained a Market Perform rating with a target of $40.00 on October 12, 2026. The consensus recommendation for the stock is to hold, with a mean price target of $44.93 from 12 analysts.
About Novo Nordisk
Novo Nordisk A/S focuses on researching, developing, manufacturing, and distributing pharmaceutical products, particularly in diabetes care and rare diseases. The company's recent share increase reflects confidence in its ongoing product development and market position.
Bottom Line
Investors should keep an eye on Novo Nordisk's upcoming earnings report on November 4, 2026, as well as any further institutional filings that may impact its stock performance.
Related Filing Alerts
Source: Chicago Partners Investment Group's 13F filing on $NVO (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts